Metabolic diseases and pro- and prebiotics: Mechanistic insights

Nutrition & Metabolism

Stanley T Omaye¹  Yukiko K Nakamura¹ 

[1] Department of Agriculture, Nutrition, and Veterinary Sciences, University of Nevada Reno, Reno, NV, 89557, USA

关键词: Prebiotics;    Probiotics;    Intestinal bacteria;    Lipopolysaccharides;    Inflammation;    Type 2 diabetes;    Obesity;   

Others  :  815251
DOI  :  10.1186/1743-7075-9-60

 received in 2012-03-29, accepted in 2012-06-19,  发布年份 2012

【 摘 要 】

Metabolic diseases, such as obesity and type 2 diabetes, are world-wide health problems. The prevalence of metabolic diseases is associated with dynamic changes in dietary macronutrient intake during the past decades. Based on national statistics and from a public health viewpoint, traditional approaches, such as diet and physical activity, have been unsuccessful in decreasing the prevalence of metabolic diseases. Since the approaches strongly rely on individual’s behavior and motivation, novel science-based strategies should be considered for prevention and therapy for the diseases. Metabolism and immune system are linked. Both overnutrition and infection result in inflammation through nutrient and pathogen sensing systems which recognize compounds with structural similarities. Dietary macronutrients (fats and sugars) can induce inflammation through activation of an innate immune receptor, Toll-like receptor 4 (TLR4). Long-term intake of diets high in fats and meats appear to induce chronic systemic low-grade inflammation, endotoxicity, and metabolic diseases. Recent investigations support the idea of the involvement of intestinal bacteria in host metabolism and preventative and therapeutic potentials of probiotic and prebiotic interventions for metabolic diseases. Specific intestinal bacteria seem to serve as lipopolysaccharide (LPS) sources through LPS and/or bacterial translocation into the circulation due to a vulnerable microbial barrier and increased intestinal permeability and to play a role in systemic inflammation and progression of metabolic diseases. This review focuses on mechanistic links between metabolic diseases (mainly obesity and type 2 diabetes), chronic systemic low-grade inflammation, intestinal environment, and nutrition and prospective views of probiotic and prebiotic interventions for the diseases.

【 授权许可】

   
2012 Nakamura and Omaye; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 1.

【 参考文献 】

• [1]Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
• [2]Ogden CL, Carroll MD: Prevalence of obesity among children and adolescents: United States, Trends 1963–1965 through 2007–2008. In Centers of Disease Control and Prevention, National Center for Health Statistics June 2010. Atlanta; 2010:1-5.
• [3]Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006, 295:1549-1555.
• [4]Wright JD, Kennedy-Stephenson J, Wang CY, McDowell MA, Johnson CL: Trends in intake of energy and macronutrients: United States, 1971–2000. In Centers of Disease Control and Prevention. Atlanta; 2004:80-82.
• [5]Chanmugam P, Guthrie JF, Cecilio S, Morton JF, Basiotis PP, Anand R: Did fat intake in the United States really decline between 1989-1991 and 1994-1996? J Am Diet Assoc 2003, 103:867-872.
• [6]Huang TT, Howarth NC, Lin BH, Roberts SB, McCrory MA: Energy intake and meal portions: associations with BMI percentile in U.S. children. Obes Res 2004, 12:1875-1885.
• [7]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
• [8]Centers of Disease Control and Prevention: Diabetes[http://www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm#aag] webcite
• [9]Gross LS, Li L, Ford ES, Liu S: Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004, 79:774-779.
• [10]Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
• [11]Vincent HK, Innes KE, Vincent KR: Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 2007, 9:813-839.
• [12]Styskal J, Remmen HV, Richardson A, Salmon AB: Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Free Radical Biol Med 2012, 52:46-58.
• [13]Ji Y, Sakata Y, Tso P: Nutrient-induced inflammation in the intestine. Curr Opin Clin Nutr 2011, 14:315-321.
• [14]Ding S, Lund PK: Role of intestinal inflammation as an early event in obesity and insulin resistance. Curr OpinClin Nutr 2011, 14:328-333.
• [15]Erridge C: The capacity of food stuffs to induce innate immune activation of human monocytes in vitro is dependent on food content of stimulants of Toll-like receptors 2 and 4. Br J Nutr 2011, 105:15-23.
• [16]Todar K: Online Textbook of Bacteriology. 2011. Bacterial Endotoxin. [textbookofbacteriology.net/endotoxin.html webcite]
• [17]Bates JM, Akerlund J, Mittge E, Guillemin K: Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in response to the gut microbiota. Cell Host Microbe 2009, 2:371-382.
• [18]Erridge C: Accumulation of stimulants of Toll-like receptor (TLR)-2 and TLR4 in meat products stored at 5'C. J Food Sci 2011, 76:H72-79.
• [19]Deopurkar R, Ghanim H, Friedman J, Abuaysheh S, Sia CL, Mohanty P, Viswanathan P, Chaudhuri A, Dandona P: Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010, 33:991-997.
• [20]Jialal I, Huet BA, Kaur H, Chien A, Devaraj S: Increased Toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012, 35:900-904.
• [21]Ghoshal S, Witta J, Zhong J, de Williers W, Eckhardt E: Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009, 50:90-97.
• [22]Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C, Porsti I, Rissanen A, Kaprio J, Mustonen J, Groop PH, Lehto M: Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011, 34:1809-1815.
• [23]Nakarai H, Yamashita A, Nagayasu S, Iwashita M, Kumamoto S, Ohyama H, Hata M, Soga Y, Kushiyama A, Asano T, Abiko Y, Nishimura F: Adopocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications. Innate Immun 2011, 18:164-170.
• [24]Sun L, Yu Z, Ye X, Zou S, Li H, Yu D, Wu H, Chen Y, Dore J, Clement K, Hu FB, Lin X: A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010, 33:1925-1932.
• [25]Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
• [26]Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I: High glucose induced Toll-like receptor expression in human monocytes. Diabetes 2008, 57:3090-3098.
• [27]Lee JY, Sohn KH, Rhee SH, Hwang D: Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001, 276:16683-16689.
• [28]Wong SW, Kwon MJ, Choi AMK, Kim HP, Nakahara K, Hwang DH: Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009, 284:27384-27392.
• [29]Dandona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS: Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistence. Exp Mol Med 2010, 42:245-253.
• [30]Nijhuis J, Rensen SS, Slaats Y, van Dielen FMH, Buurman WA, Greve JWM: Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity 2009, 17:2014-2018.
• [31]Kelley DS, Adkins Y: Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. P Nutr Soc 2012, 28:1-10.
• [32]Fedor D, Kelley DS: Prevention of insulin resistance by n-3 polyunsaturarted fatty acids. Curr Opin Clin Nutr 2009, 12:138-146.
• [33]Kalupahana NS, Claycombe KJ, Newman SJ, Stewart T, Siriwardhana N, Mathhan N, Lichtenstein AH, Moustaid-Moussa N: Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr 2010, 140:1915-1922.
• [34]Kalupahana NS, Claycombe KJ, Moustaid-Moussa N: (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr 2011, 2:304-316.
• [35]Frauss JH, Seydel U, Weckesser J, Mayer H: Structural analysis of the nontoxic lipid A of Rhodobacter capsulatus 37b4. Eur J Biochem 1989, 180:519-526.
• [36]Qureshi N, Takayama K, Kurtz R: Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect Immun 1991, 59:441-444.
• [37]Lawson RE, Moss AR, Givens DI: The role of dairy products in supplying conjugated linoleic acid to man’s diet: a review. Nutr Res Rev 2001, 14:153-172.
• [38]Kishino S, Ogawa J, Omura Y, Matsumura K, Shimuzu S: Conjugated linoleic acid production from linoleic acid by lactic acid bacteria. JAOCS 2002, 79:159-163.
• [39]Belury MA: Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr 2002, 22:505-531.
• [40]Kennedy A, Martinez K, Schmidt S, Mandrup S, Lapoint K, McIntosh MK: Antiobesity mechanisms of action of conjugated linoleic acid. J Nutr Biochem 2010, 21:171-179.
• [41]Nakamura YK, Omaye ST: Conjugated linoleic acid modulation of risk factors associated with atherosclerosis. Nutr Metab 2008, 5:22. BioMed Central Full Text
• [42]Bassaganya-Riera J, Hontecillas R: Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr 2010, 13:569-573.
• [43]Bougnoux P, Hajiaji N, Maheo K, Couet C, Chevalier S: Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. Prog Lipid Res 2010, 49:76-86.
• [44]Nakamura YK, Omaye ST: Conjugated linoleic acid isomers' roles in the regulation of PPARγ and NF-кBDNA binding and subsequent expression of antioxidant enzymes in human umbilical vein endothelial cells. Nutrition 2009, 25:800-811.
• [45]Nakamura YK, Dubick MA, Omaye ST: Modulation of oxidative stress by gamma-glutamylcysteine (GGC) and conjugated linoleic acid (CLA) in human umbilical vein endothelial cells. Food Chem Tox 2012, 50:1854-1859.
• [46]Nakamura YK, Omaye ST: Lipophilic compound-mediated gene expression and implication for intervention in reactive oxygen species (ROS)-related diseases: mini-review. Nutrients 2010, 2:725-736.
• [47]Schoeller DA, Watras AC, Whigham LD: A meta-analysis of the effects of conjugated linoleic acid on fat-free mass in humans. Appl Physiol Nutr Me 2009, 34:975-978.
• [48]Whigham LD, Watras AC, Schoeller DA: Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr 2007, 85:1203-1211.
• [49]Dandona P, Ghanim H, Bandyopadhyay A, Korzeniewski K, Ling Sia C, Chaudhuri A: Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care 2010, 33:2416-2423.
• [50]Dandona P, Chaudhuri A, Ghanim H, Mohanty P: Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009, 53:S14-S20.
• [51]Dasu MR, Jialal I: Free fatty acids in the presence of hugh glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol- Endoc 2011, 300:E145-154.
• [52]Abel ED, Peroni O, Kim JK, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001, 409:729-733.
• [53]Armoni M, Harel C, Bar-Yoseph F, Milo S, Karnieli E: Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. J Biol Chem 2005, 280:34786-34795.
• [54]Karnieli E, Armoni M: Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology. Am J Physiol-Endoc 2008, 295:E38-E45.
• [55]Franchini M, Monnais E, Seboek D, Radimerski T, Zini E, Kaufmann K, Lutz T, Reusch C, Ackermann M, Muller B, Linscheid P: Insulin resistance and increased lipolysis in bone marrow derived adipocytes stimulated with agonists of Toll like receptors. Horm Metab Res 2010, 42:703-709.
• [56]Janeway CAJr, Travers P, Walport M, Shlomchik MJ: Adaptive Immunity to Infection, in Immunobiology. In Immunobiology: the immune system in health and disease. 6th edition. Edited by Bachmann M, Casadevall A, Doherty P, Hengartner H, McGhee J, Potter M. Garland Science, New York; 2005:409-459.
• [57]Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
• [58]Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI: Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291:881-884.
• [59]DiBaise JK, Zhang H, Crowell MD, Karajmalnik-Brown R, Decker GA, Rittmann BE: Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008, 83:460-469.
• [60]Hildebrandt MA, Hoffmann C, Shrerrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD: High fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137(Hoffmann C):1716-1724.
• [61]Brugman S, Klatter FA, Visser JTJ, Wildeboer-Veloo ACM, Harmsen HJM, Rozing J, Bos NA: Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the developmet of type 1 diabetes? Diabetologia 2006, 49:2105-2108.
• [62]De La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE: Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastr 2010, 299:G440-448.
• [63]Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI: Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
• [64]Backhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. PNAS 2007, 104:979-984.
• [65]Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R: Changes in gut microbiota control metabolic enfotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
• [66]Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, Chen KT, Moss AK, Ramasamy S, Faruqui A, Hodin S, Malo PS, Ebrahimi F, Biswas B, Narisawa S, Millan JL, Warren HS, Kaplan JS, Kitts CL, Hohmann EL, Hodin RA: Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 2010, 59:1476-1484.
• [67]Sekirov I, Russell SL, Antunes CM, Finlay BB: Gut microbiota in health and disease. Physiol Rev 2010, 90:859-904.
• [68]Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Raurtonen N, Sansonetti PJ, Burcelin R: Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011, 3:559-572.
• [69]Fuller R: Probiotics in man and animals. J Appl Bacteriol 1989, 66:365-378.
• [70]Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A: Prebiotic effects: metabolic and health benefits. Br J Nutr 2010, 104:S1-S63.
• [71]Yan F, Polk DB: Probiotics and immune health. Curr Opin Gastroen 2011, 27:496-501.
• [72]Parracho H, McCartney AL, Gibson GR: Probiotics and prebiotics in infant nutrition. Proc Nutr Soc 2007, 66:405-411.
• [73]Rautava S, Kalliomaki M, Isolauri E: Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection agaist atopic disease in the infant. J Allergy Clin Immun 2002, 109:119-121.
• [74]Bjorksten B: Evidence of probiotics in prevention of allergy and asthma. Curr Drug Targets. Inflam Allergy 2005, 4:599-604.
• [75]Delzenne NM, Neyrinck AM, Backhed F, Cani PD: Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nature Rev Endocrinol 2011, 7:639-646.
• [76]Everard A, Lazarevis V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, van Holle A, Francois P, de Vos WM, Delzenne NM, Schrenzel J, Cani PD: Response of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011, 60:2775-2786.
• [77]Parnell JA, Reimer RA: Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroides and Frimicutes in lean and obese JCR:LA-cp rats. Br J Nutr 2011, 18:1-13.
• [78]Cani PD, Delzenne NM: The gut microbiome as therapeutic target. Pharm Therapuet 2011, 130:202-212.
• [79]Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH: Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta 2006, 1761:736-744.
• [80]Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A: Prebiotic effects: metabolic and health benefits. Br J Nutr 2007, 104:S1-S63.
• [81]He F, Morita H, Ouwehand AC: Bifidobacteria and Lactobacilli exhibited different mitogenic activity on murine splenocytes. Int J Prob Preb 2006, 1:77-82.
• [82]Roller M, Rechkemmer G, Waltzl B: Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J Nutr 2004, 134:153-156.
• [83]Lee YK, Ho PS, Low CS, Arvilommi H, Salminen S: Permanent colonization by Lactobacillus casei is hindered by the low rate of cell devision in mouse gut. Appl Environ Microb 2004, 70:670-674.
• [84]Bezkorovainy A: Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 1998, 73:399S-405S.
• [85]Roessler A, Forssten SD, Glei M, Ouwehand AC, Jahreis G: The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: a randomized, placebo-controlled study. Clin Nutr 2011, 31:22-29.
• [86]Roesch LF, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Mai V, Wasserfall CH, Schatz D, Atkinson MA, Neu J, Triplett EW: Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J 2009, 3:536-548.
• [87]Million M, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, Valero R, Raccah D, Vialettes B, Raoult D: Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obesin press
• [88]Zhao X, Liu XW, Xie N, Wang XH, Cui Y, Yang JW, Chen LL, Lu FG: Lactobacillus species shift in distal esophagus of high-fat-diet-fed rats. World J Gastroentero 2011, 17:3151-3157.
• [89]Danielson AD, Peo ERJ, Shahani KM, Lewis AJ, Whalen PJ, Amer MA: Anticholesteremic property of Lactobacillus acidophilus yogurt fed to mature boars. J Anim Sci 1989, 67:966-974.
• [90]Tien MS, Girardin SE, Regnault B, Bourhis LL, Dillies MA, Coppee JY, Bourdet-Sicard R, Sansonetti PJ, Pedron T: Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. Immun 2006, 176:1228-1237.
• [91]Eun CS, Han DS, Lee SH, Jeon YC, Sohn JH, Kim YS, Lee J: Probiotics may reduce inflammation by enhancing peroxisome proliferator activated receptor gamma activation in HT-29 cells. Korean J Gastroentero 2007, 49:139-146.
• [92]Ewaschuk JB, Walker JW, Diaz H, Madsen KL: Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr 2006, 136:1483-1487.
• [93]Kennedy A, Martinez K, Chung S, LaPoint K, Hopkins R, Schmidt SF, Andersen K, Mandrup S, McIntosh MK: Inflammation and insulin resistance induced by trans-10, cis-12 conjugated linoleic acid depend on intracellular calcium levels in primary cultures of human adipocytes. J Lipid Res 2010, 51:1906-1917.
• [94]Martinez K, Kennedy A, West T, Milatovic D, Aschner M, McIntosh MK: Trans-10, cis-12 conjugated linoleic acid instigates inflammation in human adpocytes compared to preadipocytes. J Biol Chem 2010, 285:17701-17712.
• [95]Halade GV, Rahman A, Fernandes G: Differential effects of conjugated linoleic acid isomers in insulin-resistant female C57BI/6J mice. J Nutr Biochem 2010, 21:332-337.
• [96]Bassaganya-Riera J, Viladomiu M, Pedradosa M, De Simone C, Carbo A, Shaykhutdinov R, Jobin C, Arthur JC, Corl BA, Vogel H, Storr M, Hontecillas R: Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPARγ to suppress colitis. PLoS ONE 2012, 7:e31238.
• [97]Kumar AS, Mody K, Jha B: Bacterial exopolysaccharides - a perception. J Basic Microb 2007, 47:103-117.
• [98]Ruas-Madiedo P, Gueimonde M, Margolles A, DlR-G CG, Salminen S: Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. J Food Protect 2006, 69:2011-2015.
• [99]Ruas-Madiedo P, Medrano M, Salazar N, DLR-G CG, Perez PF, Abraham AG: Exopolysaccharides produced by Lactobacillus and Bifidobacterium strains abrogate in vitro the cytotoxic effect of bacterial toxins on eukaryotic cells. J Appl Microb 2010, 109:2079-2086.
• [100]Ismail B, Nampoothiri KM: Production, purification and structural characterization of an exopolysaccharide produced by a probiotic Lactobacillus plantarum MTCC9510. Arch Microbiol 2010, 192:1049-1057.
• [101]Wu MH, Pan TM, Wu YJ, Chang SJ, Chang MS, Hu CY: Exopolysaccharide activities from probiotic bifidobacterium: Immunomodulatory effects (on J774A.1 macrophages) and antimicrobial properties. Int J Food Microbiol 2010, 144:104-110.
• [102]Vinderola G, Perdigon G, Duarte J, Farnworth E, Matar C: Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine 2006, 36:254-260.
• [103]Cho EJ, Hwang HJ, Kim SW, Oh JY, Baek YM, Choi JW, Bae SH, Yun JW: Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformisand Phellinus baumii in ob/ob mice. Appl Microbiol Biot 2007, 75:1257-1265.
• [104]Uchida M, Ishii I, Inoue C, Akisato Y, Watanabe K, Hosoyama S, Toida T, Ariyoshi N, Kitada M: Kefiran reduces atherosclerosis in rabbits fed a high cholesterol diet. J Atherosclerosis Thromb 2010, 17:980-988.
• [105]Liu CF, Tseng KC, Chiang SS, Lee BH, Hsu WH, Pan TM: Immunomodulatory and antioxidantpotential of Lactobacillus exopolysaccharides. J Sci Food Agr 2011, 91:2284-2291.
• [106]Delzenne NM, Neyrinck AM, Cani PD: Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. MicrobCell Fact 2011, 10:S10. BioMed Central Full Text